TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01845272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 32mg, amlodipine 10mg
Description: Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 32mg, amlodipine 10mg
Description: Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 32mg, amlodipine 10mg
Description: Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
Study: NCT01318551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: single dose, 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: single dose, 40 mg (optional)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-3934
Description: single dose, 80 mg (optional)
Study: NCT02464553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periradicular therapy (PRT)
Description: RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periradicular therapy (PRT)
Description: RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
Study: NCT02259972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113823 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113823 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat, high calorie breakfast
Description: only for dose group 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat, high calorie breakfast
Description: only for dose group 5
Study: NCT01055795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, Everolimus and LBH589
Description: Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~1. 3-6, All study drugs administered per dose level~2. 3-6, All study drugs administered per dose level~3. 3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B \& C; 30, Recommended Phase II Dose for all three compounds
Study: NCT01038960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 3 months supervised interval training
Study: NCT05954650

Intervention type: BEHAVIORAL
Intervention: Rehabilitation
Description: Physical therapy and multisensory stimulation adjusted to the needs of each patient.
Study: NCT01469351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.~Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.~Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.~1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non-active study drug
Description: placebo
Study: NCT03808311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment strategy regarding different systolic BP goals
Description: The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (\<120 mmHg in the intensive arm and \<140 mmHg in the standard arm).

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment strategy regarding different systolic BP goals
Description: The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (\<120 mmHg in the intensive arm and \<140 mmHg in the standard arm).
Study: NCT02922764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGX-104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGX-104
Study: NCT00027053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: 50 to 150 mg qhs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03853616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
Study: NCT00574899

Intervention type: OTHER
Intervention: Questioners, blood specimens, prostate tissue specimens
Description: You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat.

Intervention type: OTHER
Intervention: Questioners, blood specimens, prostate tissue specimens
Description: You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat.
Study: NCT02619513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
Study: NCT03686007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive MSM intervention handbook

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive MSM intervention research nurse coaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive ASCO print materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive CRA assistance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: View the MSM intervention videos

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Media Intervention
Description: View ASCO Cancer.net videos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04521764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein
Description: Given IT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein
Description: Given IT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT02619513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Group GE\\GT\\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
Study: NCT03904147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriClipTM Device
Description: Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TriClipTM Device
Description: Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriClipTM Device
Description: Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriClipTM Device
Description: Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
Study: NCT03191058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy
Description: MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy
Description: In the ECT arm treatment, the MECTA spectrum 5000Q or the MECTA Sigma devices will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
Study: NCT03184389

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prompt to use smartphone apps for stress management
Description: Study smartphone and software will be used to deliver intervention prompts to use stress management applications on the study smartphone at various times throughout the day, during at least 10 days of study participation. The delivery of prompts will be micro randomized to occur when participants are classified as stressed, and when participants are not classified as stressed. Headspace, a commercial stress management application, will be installed on the study smartphones. Thought Shakeup and Mood Surfing, stress management applications that are not commercially available, also will be installed on the study smartphones. These smartphone applications guide participants through stress management exercises that draw upon techniques from mindfulness, cognitive behavioral therapy, and acceptance and commitment therapy.
Study: NCT03351244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: 28 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: 28 week treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 28 week treatment period
Study: NCT02200224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Testing
Study: NCT02619513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Group GE\\GT\\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Group GE\\GT\\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindray M7 series
Description: Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindray M7 series
Description: Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
Study: NCT02189447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous Photorefractive Keratectomy and Collagen Cross-linking in patients with keratoconus
Description: Photorefractive Keratectomy followed by Collagen Cross-linking in patients with keratoconus in the same surgical setting
Study: NCT02474706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefoxitin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipenem
Study: NCT03300336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRIDE
Description: Implementation of STRIDE inpatient hospital mobility program
Study: NCT03097315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg CLS-TA Suprachoriodal Injection
Description: CLS-TA, 40 mg/mL (4 mg in 100 microliters), will be administered as a single injection at 2 timepoints
Study: NCT04601285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)
Description: Dose escalation period: JS108 is administered intravenously every three weeks (Q3W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: JS108 is administered intravenously Q3W at the corresponding dose.~Clinical expansion period: JS108 is administered intravenously Q3W at the recommended dose.
Study: NCT03890939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP AutoSV Advanced System One
Description: A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dreamstation BiPaP AutoSV
Description: A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ResMed S7 VPAP Adapt Device
Description: A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
Study: NCT02306161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Surgical Procedure
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Surgical Procedure
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03436290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention
Description: These patients will receive the palliative care intervention.
Study: NCT04007562

Intervention type: DRUG
Intervention: Hydroxychloroquine Sulfate
Description: The dosage and the route of administration of Hydroxychloroquine Sulfate was the same than in Lupus disease:~Oral administration: administered in soluble form in patients under the age of 6 years old and administered in tablets in patients other the age of 6 years old with Lipin-1 deficiency.~The soluble form was prepared at the Necker Hospital Pharmacy. Dose: 6.5 mg/kg/day (max 400 mg/day). The plasma concentration of the drug during follow-up was made, in order to follow a possible overdose.
Study: NCT03872778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]-NeoB
Description: \[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]-NeoB
Description: \[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]-NeoB
Description: \[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]-NeoB
Description: \[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]-NeoB
Description: \[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion
Study: NCT02922764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGX-104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT03872778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]-NeoB
Description: \[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion
Study: NCT02922764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT03872778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]-NeoB
Description: \[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]-NeoB
Description: \[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]-NeoB
Description: \[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]-NeoB
Description: \[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoB
Description: \[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoB
Description: \[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoB
Description: \[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoB
Description: \[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoB
Description: \[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoB
Description: \[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoB
Description: \[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoB
Description: \[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoB
Description: \[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-NeoB
Description: \[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: dose strength 49/51 mg, film-coated tablets for oral use
Study: NCT02922764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed